BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Faerch K, Vaag A, Holst JJ, Glümer C, Pedersen O, Borch-Johnsen K. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia. 2008;51:853-861. [PMID: 18317726 DOI: 10.1007/s00280-008-0711-0] [Cited by in Crossref: 174] [Cited by in F6Publishing: 151] [Article Influence: 13.4] [Reference Citation Analysis]
Number Citing Articles
1 Aapro M, Launay-vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treatment Reviews 2012;38:235-40. [DOI: 10.1016/j.ctrv.2011.05.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
2 dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 2012;86:1233-50. [PMID: 22382776 DOI: 10.1007/s00204-012-0821-7] [Cited by in Crossref: 216] [Cited by in F6Publishing: 204] [Article Influence: 24.0] [Reference Citation Analysis]
3 Ojha S, Venkataraman B, Kurdi A, Mahgoub E, Sadek B, Rajesh M. Plant-Derived Agents for Counteracting Cisplatin-Induced Nephrotoxicity. Oxid Med Cell Longev 2016;2016:4320374. [PMID: 27774117 DOI: 10.1155/2016/4320374] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
4 Fahmi ANA, Shehatou GSG, Shebl AM, Salem HA. Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury. Naunyn-Schmiedeberg's Arch Pharmacol 2016;389:819-30. [DOI: 10.1007/s00210-016-1258-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
5 Zhou Y, Hou J, Yang G, Jiang S, Chen C, Wang Z, Liu Y, Ren S, Li W. Icariin ameliorates cisplatin-induced cytotoxicity in human embryonic kidney 293 cells by suppressing ROS-mediated PI3K/Akt pathway. Biomedicine & Pharmacotherapy 2019;109:2309-17. [DOI: 10.1016/j.biopha.2018.11.108] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
6 Lebel A, Chui H, McMahon KR, Lim YJ, Macri J, Wang S, Devarajan P, Blydt-Hansen TD, Zappitelli M, Urquhart BL. Association of Urine Platinum With Acute Kidney Injury in Children Treated With Cisplatin for Cancer. J Clin Pharmacol 2021;61:871-80. [PMID: 33599997 DOI: 10.1002/jcph.1839] [Reference Citation Analysis]
7 Li S, Nagothu K, Ranganathan G, Ali SM, Shank B, Gokden N, Ayyadevara S, Megyesi J, Olivecrona G, Chugh SS, Kersten S, Portilla D. Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury. Am J Physiol Renal Physiol 2012;303:F437-48. [PMID: 22622461 DOI: 10.1152/ajprenal.00111.2012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
8 Faig J, Haughton M, Taylor RC, D'Agostino RB Jr, Whelen MJ, Porosnicu Rodriguez KA, Bonomi M, Murea M, Porosnicu M. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy. Am J Clin Oncol 2018;41:432-40. [PMID: 27281266 DOI: 10.1097/COC.0000000000000301] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
9 Kanehira Y, Togami K, Ishizawa K, Sato S, Tada H, Chono S. Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer. Pharmaceutical Development and Technology 2019;24:1095-103. [DOI: 10.1080/10837450.2019.1633345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rubera I, Duranton C, Melis N, Cougnon M, Mograbi B, Tauc M. Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity. Cell Death Dis. 2013;4:e817. [PMID: 24091660 DOI: 10.1038/cddis.2013.355] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
11 Xie Y, Aillon KL, Cai S, Christian JM, Davies NM, Berkland CJ, Forrest ML. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm 2010;392:156-63. [PMID: 20363303 DOI: 10.1016/j.ijpharm.2010.03.058] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
12 Kuang Y, Liu J, Liu Z, Zhuo R. Cholesterol-based anionic long-circulating cisplatin liposomes with reduced renal toxicity. Biomaterials 2012;33:1596-606. [PMID: 22079777 DOI: 10.1016/j.biomaterials.2011.10.081] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
13 Porceddu SV, Scotté F, Aapro M, Salmio S, Castro A, Launay-Vacher V, Licitra L. Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. Front Oncol 2019;9:1522. [PMID: 32039012 DOI: 10.3389/fonc.2019.01522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ravichandran K, Holditch S, Brown CN, Wang Q, Ozkok A, Weiser-Evans MC, Nemenoff R, Miyazaki M, Thiessen-Philbrook H, Parikh CR, Ljubanovic D, Edelstein CL. IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 2018;314:F356-66. [PMID: 29070568 DOI: 10.1152/ajprenal.00040.2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
15 Gauvin DV, Zimmermann ZJ, Yoder J, Tapp R, Baird TJ. Predicting the Need for a Tier II Ototoxicity Study From Early Renal Function Data. Int J Toxicol 2019;38:265-78. [PMID: 31220989 DOI: 10.1177/1091581819851232] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ghadrdan E, Ebrahimpour S, Sadighi S, Chaibakhsh S, Jahangard-Rafsanjani Z. Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin. J Oncol Pharm Pract 2020;26:1643-9. [PMID: 32046578 DOI: 10.1177/1078155220901756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Tixier F, Ranchon F, Iltis A, Vantard N, Schwiertz V, Bachy E, Bouafia-sauvy F, Sarkozy C, Tournamille JF, Gyan E, Salles G, Rioufol C. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients: Platinum-containing chemotherapy regimens. Hematological Oncology 2017;35:584-90. [DOI: 10.1002/hon.2328] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
18 Ghonaim E, El-Haggar S, Gohar S. Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial. Med Oncol 2021;38:108. [PMID: 34357466 DOI: 10.1007/s12032-021-01558-y] [Reference Citation Analysis]
19 Panesso MC, Shi M, Cho HJ, Paek J, Ye J, Moe OW, Hu MC. Klotho has dual protective effects on cisplatin-induced acute kidney injury. Kidney Int 2014;85:855-70. [PMID: 24304882 DOI: 10.1038/ki.2013.489] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 8.1] [Reference Citation Analysis]
20 Launay-vacher V. Epidemiology of Chronic Kidney Disease in Cancer Patients: Lessons From the IRMA Study Group. Seminars in Nephrology 2010;30:548-56. [DOI: 10.1016/j.semnephrol.2010.09.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
21 Shahbazi F, Farvadi F, Dashti-khavidaki S, Ataei S, Shojaei L. Potential nephroprotective effects of resveratrol in drug induced nephrotoxicity: a narrative review of safety and efficacy data. ADV TRADIT MED (ADTM) 2020;20:529-44. [DOI: 10.1007/s13596-020-00432-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 El Hamamsy M, Kamal N, Bazan NS, El Haddad M. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study. Int J Clin Pharm 2018;40:1539-47. [PMID: 30167970 DOI: 10.1007/s11096-018-0677-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Lameire N, Van Biesen W, Vanholder R. Acute renal problems in the critically ill cancer patient. Curr Opin Crit Care 2008;14:635-46. [PMID: 19005304 DOI: 10.1097/MCC.0b013e32830ef70b] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
24 Stampler KM, Holtz DO, Dunton CJ. Reducing excessive toxicity in ovarian cancer treatment: a personalized approach. Future Oncology 2011;7:789-98. [DOI: 10.2217/fon.11.55] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Inai H, Kawai K, Ikeda A, Ando S, Kimura T, Oikawa T, Onozawa M, Miyazaki J, Uchida K, Nishiyama H. Risk factors for chronic kidney disease after chemotherapy for testicular cancer. Int J Urol 2013;20:716-22. [PMID: 23186076 DOI: 10.1111/iju.12017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
26 Bégin AM, Monfette ML, Boudrias-Dalle É, Lavallée E, Samouelian V, Soulières D, Chagnon M, Fournier MA, Letarte N, Adam JP. Effect of mannitol on acute kidney injury induced by cisplatin. Support Care Cancer 2021;29:2083-91. [PMID: 32862356 DOI: 10.1007/s00520-020-05703-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Chen Y, Brott D, Luo W, Gangl E, Kamendi H, Barthlow H, Lengel D, Fikes J, Kinter L, Valentin J, Bialecki R. Assessment of cisplatin-induced kidney injury using an integrated rodent platform. Toxicology and Applied Pharmacology 2013;268:352-61. [DOI: 10.1016/j.taap.2013.01.032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
28 Waly MI, Al Moundhri MS, Ali BH. Effect of curcumin on cisplatin- and oxaliplatin-induced oxidative stress in human embryonic kidney (HEK) 293 cells. Ren Fail 2011;33:518-23. [PMID: 21574897 DOI: 10.3109/0886022X.2011.577546] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
29 Hunter RJ, Pace MB, Burns KA, Burke CC, Gonzales DA, Webb NF, Levenback CF, Jhingran A, Parker C, Munsell MF, Smith JA. Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment. Support Care Cancer 2009;17:1195-201. [DOI: 10.1007/s00520-008-0574-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Phan NT, Heng AE, Lautrette A, Kémény JL, Souweine B. Oxaliplatin-induced acute renal failure presenting clinically as thrombotic microangiopathy: think of acute tubular necrosis. NDT Plus 2009;2:254-6. [PMID: 25984004 DOI: 10.1093/ndtplus/sfp008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
31 Hamroun A, Lenain R, Bigna JJ, Speyer E, Bui L, Chamley P, Pottier N, Cauffiez C, Dewaeles E, Dhalluin X, Scherpereel A, Hazzan M, Maanaoui M, Glowacki F. Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis. Drugs 2019;79:1567-82. [PMID: 31429065 DOI: 10.1007/s40265-019-01182-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
32 Klöckl MC, Kasparek AK, Riedl JM, Moik F, Mollnar S, Stotz M, Szkandera J, Terbuch A, Gerger A, Niedrist T, Pichler M, Bauernhofer T, Schilcher G, Zitta S, Rosenkranz AR, Friedl C, Stöger H, Posch F. Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy. Sci Rep 2020;10:11219. [PMID: 32641710 DOI: 10.1038/s41598-020-68010-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sherif IO. Amelioration of cisplatin-induced nephrotoxicity in rats by triterpenoid saponin of Terminalia arjuna. Clin Exp Nephrol 2015;19:591-7. [PMID: 25389052 DOI: 10.1007/s10157-014-1056-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
34 Zimmer-rapuch S, Lheureux S, Brocard F, Janus N, Launay-vacher V, Ray-coquard I. Gestion des agents anticancéreux chez les insuffisants rénaux. Bulletin du Cancer 2012;99:323-31. [DOI: 10.1684/bdc.2011.1489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Yang YI, Ahn JH, Choi YS, Choi JH. Brown algae phlorotannins enhance the tumoricidal effect of cisplatin and ameliorate cisplatin nephrotoxicity. Gynecol Oncol 2015;136:355-64. [PMID: 25462204 DOI: 10.1016/j.ygyno.2014.11.015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
36 Yaman O, Topcu-tarladacalisir Y. L-carnitine counteracts prepubertal exposure to cisplatin induced impaired sperm in adult rats by preventing germ cell apoptosis. Biotechnic & Histochemistry 2018;93:157-67. [DOI: 10.1080/10520295.2017.1401661] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
37 Prša P, Karademir B, Biçim G, Mahmoud H, Dahan I, Yalçın AS, Mahajna J, Milisav I. The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics. Biochemical Pharmacology 2020;173:113551. [DOI: 10.1016/j.bcp.2019.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
38 Mahmoodnia L, Mohammadi K, Masumi R. Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patient. J Nephropathol 2017;6:144-9. [PMID: 28975094 DOI: 10.15171/jnp.2017.25] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
39 Hollevoet K, Speeckaert MM, Decavele AS, Vanholder R, van Meerbeeck JP, Delanghe JR. Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption. Clin Lung Cancer 2012;13:470-4. [PMID: 22386954 DOI: 10.1016/j.cllc.2011.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
40 Kimura T, Nojiri T, Hosoda H, Ishikane S, Shintani Y, Inoue M, Miyazato M, Okumura M, Kangawa K. Protective effects of C-type natriuretic peptide on cisplatin-induced nephrotoxicity in mice. Cancer Chemother Pharmacol 2015;75:1057-63. [PMID: 25814217 DOI: 10.1007/s00280-015-2734-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
41 Máthé C, Szénási G, Sebestény A, Blázovics A, Szentmihályi K, Hamar P, Albert M. Protective effect of CV247 against cisplatin nephrotoxicity in rats. Hum Exp Toxicol 2014;33:789-99. [DOI: 10.1177/0960327113480972] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
42 Ruggiero A, Ariano A, Triarico S, Capozza MA, Romano A, Maurizi P, Mastrangelo S, Attinà G. Cisplatin-induced nephrotoxicity in children: what is the best protective strategy? J Oncol Pharm Pract 2021;27:180-6. [PMID: 32990190 DOI: 10.1177/1078155220961550] [Reference Citation Analysis]
43 Zhang D, Pan J, Xiang X, Liu Y, Dong G, Livingston MJ, Chen JK, Yin XM, Dong Z. Protein Kinase Cδ Suppresses Autophagy to Induce Kidney Cell Apoptosis in Cisplatin Nephrotoxicity. J Am Soc Nephrol 2017;28:1131-44. [PMID: 27799485 DOI: 10.1681/ASN.2016030337] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 7.2] [Reference Citation Analysis]
44 Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 2009;5:450-62. [DOI: 10.1038/nrneph.2009.97] [Cited by in Crossref: 114] [Cited by in F6Publishing: 85] [Article Influence: 9.5] [Reference Citation Analysis]
45 Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open 2016;1:e000091. [PMID: 27843635 DOI: 10.1136/esmoopen-2016-000091] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
46 Xu Q, Yan P, Duan XJ, Wu X, Chen XJ, Luo M, Peng JC, Feng LX, Liu J, Zhong HL, Cheng W, Zou QY, Duan SB. Human umbilical cord-derived mesenchymal stem cells and human cord blood mononuclear cells protect against cisplatin-induced acute kidney injury in rat models. Exp Ther Med 2020;20:145. [PMID: 33093883 DOI: 10.3892/etm.2020.9274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, Kitagawa Y, Kuwano H, Nishiyama H, Ishioka C, Takaishi H, Shimodaira H, Mogi A, Ando Y, Matsumoto K, Kadowaki D, Muto S. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol 2018;22:210-44. [PMID: 28856465 DOI: 10.1007/s10157-017-1448-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 9.3] [Reference Citation Analysis]
48 Sánchez-González PD, López-Hernández FJ, Dueñas M, Prieto M, Sánchez-López E, Thomale J, Ruiz-Ortega M, López-Novoa JM, Morales AI. Differential effect of quercetin on cisplatin-induced toxicity in kidney and tumor tissues. Food Chem Toxicol 2017;107:226-36. [PMID: 28669851 DOI: 10.1016/j.fct.2017.06.047] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
49 Gao H, Zhang S, Hu T, Qu X, Zhai J, Zhang Y, Tao L, Yin J, Song Y. Omeprazole protects against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and transporter-mediated cisplatin accumulation in rats and HK-2 cells. Chem Biol Interact 2019;297:130-40. [PMID: 30452898 DOI: 10.1016/j.cbi.2018.11.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
50 Sheshadri DB, Chakravarthy MR. Anaesthetic Considerations in the Perioperative Management of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Indian J Surg Oncol 2016;7:236-43. [PMID: 27065715 DOI: 10.1007/s13193-016-0508-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
51 Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O. Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg 2014;151:347-53. [PMID: 25168575 DOI: 10.1016/j.jviscsurg.2014.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
52 Losonczy G, Máthé C, Müller V, Szondy K, Moldvay J. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer]. Magy Onkol 2010;54:289-96. [PMID: 21163759 DOI: 10.1556/MOnkol.54.2010.4.3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Thomet FA, Pinyol P, Villena G. J, Reveco PG. Towards a more selective analogue of oxaliplatin: Synthesis of [Pt((1R,2R)-diaminocyclohexane)(3-carboxypredicentrinato)]. Inorganica Chimica Acta 2012;384:255-9. [DOI: 10.1016/j.ica.2011.12.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
54 Arai Y, Takahashi D, Asano K, Tanaka M, Oda M, Ko SBH, Ko MSH, Mandai S, Nomura N, Rai T, Uchida S, Sohara E. Salt suppresses IFNγ inducible chemokines through the IFNγ-JAK1-STAT1 signaling pathway in proximal tubular cells. Sci Rep 2017;7:46580. [PMID: 28425456 DOI: 10.1038/srep46580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquée L, De Vuyst P, Germonpré P, Kellen E, Legrand C, Kishi Y, Delanghe JR, van Meerbeeck JP. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol 2011;6:1930-7. [PMID: 21841505 DOI: 10.1097/JTO.0b013e3182272294] [Cited by in Crossref: 59] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
56 Xiang SD, Scalzo-inguanti K, Minigo G, Park A, Hardy CL, Plebanski M. Promising particle-based vaccines in cancer therapy. Expert Review of Vaccines 2014;7:1103-19. [DOI: 10.1586/14760584.7.7.1103] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
57 Guo C, Pei L, Xiao X, Wei Q, Chen JK, Ding HF, Huang S, Fan G, Shi H, Dong Z. DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8. Kidney Int 2017;92:1194-205. [PMID: 28709638 DOI: 10.1016/j.kint.2017.03.038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
58 Aoyama T, Tsunoda T, Kato H, Hagino A, Furutani R, Ito K, Yoshioka H, Nakamura M, Hiraide M, Kawakami K, Kobayashi K, Suzuki K, Ichimura T, Yamaguchi K, Hama T. Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer—a retrospective study. Journal of Chemotherapy 2020;32:144-50. [DOI: 10.1080/1120009x.2020.1713507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
59 Alam N, Koul M, Mintoo MJ, Khare V, Gupta R, Rawat N, Sharma PR, Singh SK, Mondhe DM, Gupta PN. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor. Biomedicine & Pharmacotherapy 2017;95:856-64. [DOI: 10.1016/j.biopha.2017.08.108] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
60 Ruggiero A, Rizzo D, Trombatore G, Maurizi P, Riccardi R. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not? Cancer Chemother Pharmacol 2016;77:19-26. [PMID: 26589789 DOI: 10.1007/s00280-015-2913-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
61 Lee RFS, Menin L, Patiny L, Ortiz D, Dyson PJ. Versatile Tool for the Analysis of Metal–Protein Interactions Reveals the Promiscuity of Metallodrug–Protein Interactions. Anal Chem 2017;89:11985-9. [DOI: 10.1021/acs.analchem.7b02211] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
62 Furukawa N, Kawaguchi R, Kobayashi H. Use of high-dose cisplatin with aprepitant in an outpatient setting. Eur J Cancer Care (Engl) 2012;21:436-41. [PMID: 21883567 DOI: 10.1111/j.1365-2354.2011.01284.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
63 Lopez-Hernandez FJ, Lopez-Novoa JM. Potential utility of PPARalpha activation in the prevention of ischemic and drug-induced acute renal damage. Kidney Int 2009;76:1022-4. [PMID: 19876055 DOI: 10.1038/ki.2009.229] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
64 Meyer zu Schwabedissen HE, Grube M, Kroemer HK. Pharmacogenetics of Drug Transporters. In: Maitland-van der Zee A, Daly AK, editors. Pharmacogenetics and Individualized Therapy. Hoboken: John Wiley & Sons, Inc.; 2012. pp. 101-48. [DOI: 10.1002/9781118116494.ch4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Yang H, Li W, Wang L, He X, Sun H, Zhang J. The Proteins from Sika deer antler as potential modulators on cisplatin-induced cytotoxicity in human embryonic kidney 293 cells. Natural Product Research 2018;32:1982-6. [DOI: 10.1080/14786419.2017.1356839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
66 Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in Toxicological Research of the Anticancer Drug Cisplatin. Chem Res Toxicol 2019;32:1469-86. [PMID: 31353895 DOI: 10.1021/acs.chemrestox.9b00204] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 19.5] [Reference Citation Analysis]
67 Ramón-lópez A, Escudero-ortiz V, Carbonell V, Pérez-ruixo J, Valenzuela B. Farmacocinética poblacional de cisplatino aplicada a la personalización de su dosificación en pacientes oncológicos. Farmacia Hospitalaria 2012;36:392-402. [DOI: 10.1016/j.farma.2011.08.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
68 Nagele P, Rao LK, Penta M, Kallogjeri D, Spitznagel EL, Cavallone LF, Nussenbaum B, Piccirillo JF. Postoperative myocardial injury after major head and neck cancer surgery. Head Neck 2011;33:1085-91. [PMID: 20886662 DOI: 10.1002/hed.21577] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
69 Oh GS, Kim HJ, Shen A, Lee SB, Yang SH, Shim H, Cho EY, Kwon KB, Kwak TH, So HS. New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity. Biomed Res Int 2016;2016:4048390. [PMID: 26881219 DOI: 10.1155/2016/4048390] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
70 Liu HE, Bai KJ, Hsieh YC, Yu MC, Lee CN, Chang JH, Hsu HL, Lu PC, Chen HY. Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patients. Biomed Res Int 2014;2014:937429. [PMID: 25250341 DOI: 10.1155/2014/937429] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
71 Spalato M, Italiano A. The safety of current pharmacotherapeutic strategies for osteosarcoma. Expert Opin Drug Saf 2021;20:427-38. [PMID: 33478264 DOI: 10.1080/14740338.2021.1881060] [Reference Citation Analysis]
72 Ruggiero A, Trombatore G, Triarico S, Arena R, Ferrara P, Scalzone M, Pierri F, Riccardi R. Platinum compounds in children with cancer: toxicity and clinical management. Anti-Cancer Drugs 2013;24:1007-19. [DOI: 10.1097/cad.0b013e3283650bda] [Cited by in Crossref: 79] [Cited by in F6Publishing: 28] [Article Influence: 9.9] [Reference Citation Analysis]
73 Perše M. Cisplatin Mouse Models: Treatment, Toxicity and Translatability. Biomedicines 2021;9:1406. [PMID: 34680523 DOI: 10.3390/biomedicines9101406] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Tekce BK, Uyeturk U, Tekce H, Uyeturk U, Aktas G, Akkaya A. Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage? Ann Clin Biochem 2015;52:88-94. [PMID: 24670880 DOI: 10.1177/0004563214528312] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
75 Sen Z, Jie M, Jingzhi Y, Dongjie W, Dongming Z, Xiaoguang C. Total Coumarins from Hydrangea paniculata Protect against Cisplatin-Induced Acute Kidney Damage in Mice by Suppressing Renal Inflammation and Apoptosis. Evid Based Complement Alternat Med 2017;2017:5350161. [PMID: 28367225 DOI: 10.1155/2017/5350161] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
76 Greene SN, Ramos-vara JA, Craig BA, Hooser SB, Anderson C, Fourez LM, Johnson BM, Stewart JC, Knapp DW. Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats. Cancer Chemother Pharmacol 2010;65:549-56. [DOI: 10.1007/s00280-009-1061-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
77 Sánchez-gonzález PD, López-hernández FJ, López-novoa JM, Morales AI. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Critical Reviews in Toxicology 2011;41:803-21. [DOI: 10.3109/10408444.2011.602662] [Cited by in Crossref: 134] [Cited by in F6Publishing: 136] [Article Influence: 13.4] [Reference Citation Analysis]
78 Kim D, Park W, Lee S, Kim W, Park SK, Kang KP. Absence of Sirt3 aggravates cisplatin nephrotoxicity via enhanced renal tubular apoptosis and inflammation. Mol Med Rep 2018;18:3665-72. [PMID: 30106119 DOI: 10.3892/mmr.2018.9350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
79 Kang X, Zheng X, Xu D, Su T, Zhou Y, Ji J, Yu Q, Cui Y, Yang L. A cross-sectional study of chemotherapy-related AKI. Eur J Clin Pharmacol 2021;77:1503-12. [PMID: 33993344 DOI: 10.1007/s00228-021-03115-y] [Reference Citation Analysis]
80 Zhang T, Cai S, Groer C, Forrest WC, Yang Q, Mohr E, Douglas J, Aires D, Axiak-Bechtel SM, Selting KA, Swarz JA, Tate DJ, Bryan JN, Forrest ML. Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines. J Pharm Sci 2016;105:1891-900. [PMID: 27155765 DOI: 10.1016/j.xphs.2016.03.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
81 Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457-468. [PMID: 25540591 DOI: 10.2147/ijnrd.s39747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
82 Li C, Li L, Yi Y, Wang W, Yuan J, Tan F, Fang D, Zeng S, Zhou H, Jiang H. L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy. Biochemical Pharmacology 2020;177:114021. [DOI: 10.1016/j.bcp.2020.114021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
83 Almanric K, Marceau N, Cantin A, Bertin É. Risk Factors for Nephrotoxicity Associated with Cisplatin. Can J Hosp Pharm 2017;70:99-106. [PMID: 28487576 DOI: 10.4212/cjhp.v70i2.1641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
84 Li H, Zhu C, Wu J, Ma Y, Jin X, Wei X, Wang K, Li H. Urological second malignant neoplasms in testicular nonseminoma survivors: a population-based analysis. Int Urol Nephrol 2021;53:471-7. [PMID: 33052518 DOI: 10.1007/s11255-020-02659-9] [Reference Citation Analysis]
85 Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490-518. [PMID: 22069563 DOI: 10.3390/toxins2112490] [Cited by in Crossref: 782] [Cited by in F6Publishing: 727] [Article Influence: 71.1] [Reference Citation Analysis]
86 Hakiminia B, Goudarzi A, Moghaddas A. Has vitamin E any shreds of evidence in cisplatin-induced toxicity. J Biochem Mol Toxicol 2019;33:e22349. [PMID: 31115123 DOI: 10.1002/jbt.22349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
87 Kang KP, Park SK, Kim DH, Sung MJ, Jung YJ, Lee AS, Lee JE, Ramkumar KM, Lee S, Park MH, Roh S, Kim W. Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis. Nephrology Dialysis Transplantation 2011;26:814-22. [DOI: 10.1093/ndt/gfq528] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
88 Cai S, Xie Y, Davies NM, Cohen MS, Forrest ML. Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. J Pharm Sci 2010;99:2664-71. [PMID: 19960530 DOI: 10.1002/jps.22016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
89 Crone B, Schlatt L, Nadar RA, van Dijk NWM, Margiotta N, Sperling M, Leeuwenburgh S, Karst U. Quantitative imaging of platinum-based antitumor complexes in bone tissue samples using LA-ICP-MS. Journal of Trace Elements in Medicine and Biology 2019;54:98-102. [DOI: 10.1016/j.jtemb.2019.04.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
90 Losanno T, Gridelli C. Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. Expert Opin Drug Saf 2016;15:837-51. [PMID: 27007279 DOI: 10.1517/14740338.2016.1170116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
91 Ninsontia C, Pongjit K, Chaotham C, Chanvorachote P. Silymarin selectively protects human renal cells from cisplatin-induced cell death. Pharm Biol 2011;49:1082-90. [PMID: 21591838 DOI: 10.3109/13880209.2011.568506] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
92 Puisset F, Bigay-Game L, Paludetto MN, Martel A, Perriat S, Rabeau A, Canonge JM, Mazieres J. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit. Support Care Cancer 2019;27:1679-86. [PMID: 30120556 DOI: 10.1007/s00520-018-4415-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
93 Toprak Z, Cebeci E, Helvaci SA, Toprak ID, Kutlu Y, Sakin A, Tukek T. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients. Int Urol Nephrol 2017;49:1041-7. [DOI: 10.1007/s11255-017-1556-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
94 Hübner M, Kusamura S, Villeneuve L, Al-Niaimi A, Alyami M, Balonov K, Bell J, Bristow R, Guiral DC, Fagotti A, Falcão LFR, Glehen O, Lambert L, Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar SP, Wadhwa A, Altman A, Fawcett W, Veerapong J, Nelson G. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations - Part II: Postoperative management and special considerations. Eur J Surg Oncol 2020;46:2311-23. [PMID: 32826114 DOI: 10.1016/j.ejso.2020.08.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
95 Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W. Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 2009;24:3012-20. [PMID: 19474282 DOI: 10.1093/ndt/gfp242] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 8.3] [Reference Citation Analysis]
96 Dattatri R, Garg R, Ray MD. Cytoreductive onco-surgery with combined hyperthermic intraperitoneal chemotherapy and hyperthermic intrathoracic chemotherapy: Perioperative challenges. Saudi J Anaesth 2019;13:131-5. [PMID: 31007659 DOI: 10.4103/sja.SJA_545_18] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
97 Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans 2018;47:6645-53. [DOI: 10.1039/c8dt00838h] [Cited by in Crossref: 421] [Cited by in F6Publishing: 151] [Article Influence: 140.3] [Reference Citation Analysis]
98 Ali BH, Al-salam S, Al Husseini IS, Al-lawati I, Waly M, Yasin J, Fahim M, Nemmar A. Abrogation of cisplatin-induced nephrotoxicity by emodin in rats: Emodin and cisplatin nephrotoxicity. Fundamental & Clinical Pharmacology 2013;27:192-200. [DOI: 10.1111/j.1472-8206.2011.01003.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
99 Makimoto A, Matsui M, Chin M, Koh K, Tomotsune M, Kaneko T, Morikawa Y, Yuza Y. Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: A protocol for a randomized phase 2 trial. Contemp Clin Trials Commun 2019;16:100440. [PMID: 31508533 DOI: 10.1016/j.conctc.2019.100440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Jing X, Han J, Zhang J, Chen Y, Yuan J, Wang J, Neo S, Li S, Yu X, Wu J. Long non-coding RNA MEG3 promotes cisplatin-induced nephrotoxicity through regulating AKT/TSC/mTOR-mediated autophagy. Int J Biol Sci 2021;17:3968-80. [PMID: 34671212 DOI: 10.7150/ijbs.58910] [Reference Citation Analysis]
101 Launay-vacher V, Etessami R, Janus N, Spano J, Ray-coquard I, Oudard S, Gligorov J, Pourrat X, Beuzeboc P, Deray G, Morere J; The Renal Insufficiency Anticancer Medications (IRMA) Study Group. Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues. Lung 2009;187:69-74. [DOI: 10.1007/s00408-008-9123-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
102 Nada A, Jetton JG. Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy. Pediatr Nephrol 2021;36:2227-55. [PMID: 33245421 DOI: 10.1007/s00467-020-04800-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Bauer OB, Köppen C, Sperling M, Schurek HJ, Ciarimboli G, Karst U. Quantitative Bioimaging of Platinum via Online Isotope Dilution-Laser Ablation-Inductively Coupled Plasma Mass Spectrometry. Anal Chem 2018;90:7033-9. [PMID: 29741357 DOI: 10.1021/acs.analchem.8b01429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
104 Hausheer F, Ding D, Shanmugarajah D, Leverett B, Huang Q, Chen X, Kochat H, Ayala P, Petluru P, Parker A. Accumulation of BNP7787 in Human Renal Proximal Tubule Cells. Journal of Pharmaceutical Sciences 2011;100:3977-84. [DOI: 10.1002/jps.22510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
105 Toffart AC, Belaiche S, Moro-Sibilot D, Couraud S, Sakhri L. [Impact of lung cancer treatments on renal function]. Rev Mal Respir 2014;31:1003-12. [PMID: 25496793 DOI: 10.1016/j.rmr.2014.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
106 Corbella D, Piraccini E, Finazzi P, Brambillasca P, Prussiani V, Corso MR, Germandi C, Agnoletti V. Anesthetic management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy procedures. World J Obstet Gynecol 2013; 2(4): 129-136 [DOI: 10.5317/wjog.v2.i4.129] [Cited by in CrossRef: 4] [Article Influence: 0.5] [Reference Citation Analysis]
107 Puma N, Ruggiero A, Scalzone M, Coccia P, Triarico S, Trombatore G, Mastrangelo S, Riccardi R. Platinum compounds and sodium metabolism in children with diencephalic glioma. J Neurooncol 2013;115:113-7. [DOI: 10.1007/s11060-013-1203-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
108 Niggebrugge-Mentink KL, Beex-Oosterhuis MM, Ter Horst PGJ, van de Poll MEC, Dieleman HG, van Kesteren C. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL). J Clin Pharm Ther 2020;45:1153-8. [PMID: 32533904 DOI: 10.1111/jcpt.13200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Cao X, Zhang W, Moore PK, Bian J. Protective Smell of Hydrogen Sulfide and Polysulfide in Cisplatin-Induced Nephrotoxicity. Int J Mol Sci 2019;20:E313. [PMID: 30646560 DOI: 10.3390/ijms20020313] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
110 Muthuraman A, Sood S, Singla SK, Rana A, Singh A, Singh A, Singh J. Ameliorative effect of flunarizine in cisplatin-induced acute renal failure via mitochondrial permeability transition pore inactivation in rats. Naunyn Schmiedebergs Arch Pharmacol 2011;383:57-64. [PMID: 21058009 DOI: 10.1007/s00210-010-0572-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
111 Ueki M, Ueno M, Morishita J, Maekawa N. Curcumin ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice. Journal of Bioscience and Bioengineering 2013;115:547-51. [DOI: 10.1016/j.jbiosc.2012.11.007] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 9.9] [Reference Citation Analysis]
112 Brown CN, Atwood DJ, Pokhrel D, Ravichandran K, Holditch SJ, Saxena S, Miyazaki M, Nemenoff R, Weiser-Evans MCM, Ljubanovic DG, Joy MS, Edelstein CL. The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice. Cell Signal 2020;71:109605. [PMID: 32194168 DOI: 10.1016/j.cellsig.2020.109605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Launay-vacher V, Zimner-rapuch S, Moranne O. Évaluation de la fonction rénale chez le patient atteint de cancer. Bulletin du Cancer 2012;99:277-83. [DOI: 10.1684/bdc.2011.1485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
114 Passot G, Vaudoyer D, Villeneuve L, Wallet F, Beaujard AC, Boschetti G, Rousset P, Bakrin N, Cotte E, Glehen O. A Perioperative Clinical Pathway Can Dramatically Reduce Failure-to-rescue Rates After Cytoreductive Surgery for Peritoneal Carcinomatosis: A Retrospective Study of 666 Consecutive Cytoreductions. Ann Surg. 2017;265:806-813. [PMID: 27775553 DOI: 10.1097/sla.0000000000001723] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
115 Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH, Sparreboom A. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res 2010;16:4198-206. [PMID: 20601443 DOI: 10.1158/1078-0432.CCR-10-0949] [Cited by in Crossref: 58] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
116 Pili-Floury S, Royer B, Bartholin F, Crumiere N, Combe M, Chalopin JM, Pivot X, Heyd B, Chauffert B, Samain E. Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy. Eur J Obstet Gynecol Reprod Biol 2011;156:199-203. [PMID: 21306815 DOI: 10.1016/j.ejogrb.2011.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
117 Elkady AI, Ramadan WS. The aqueous extract of cinnamon bark ameliorated cisplatin-induced cytotoxicity in vero cells without compromising the anticancer efficiency of cisplatin. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016;160:363-71. [DOI: 10.5507/bp.2016.034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
118 Skrypnyk NI, Siskind LJ, Faubel S, de Caestecker MP. Bridging translation for acute kidney injury with better preclinical modeling of human disease. Am J Physiol Renal Physiol 2016;310:F972-84. [PMID: 26962107 DOI: 10.1152/ajprenal.00552.2015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
119 Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, Schellens JH. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. Br J Clin Pharmacol 2015;80:253-66. [PMID: 25677219 DOI: 10.1111/bcp.12606] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
120 Money ME, Hamroun A, Shu Y, Matthews C, Ahmed Eltayeb S, Ciarimboli G, Metz CN. Case Report and Supporting Documentation: Acute Kidney Injury Manifested as Oliguria Is Reduced by Intravenous Magnesium Before Cisplatin. Front Oncol 2021;11:607574. [PMID: 33718160 DOI: 10.3389/fonc.2021.607574] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int 2014;2014:967826. [PMID: 25165721 DOI: 10.1155/2014/967826] [Cited by in Crossref: 260] [Cited by in F6Publishing: 265] [Article Influence: 37.1] [Reference Citation Analysis]
122 Ben Ayed W, Ben Said A, Hamdi A, Mokrani A, Masmoudi Y, Toukabri I, Limayem I, Yahyaoui Y. Toxicity, risk factors and management of cisplatin-induced toxicity: A prospective study. J Oncol Pharm Pract 2020;26:1621-9. [DOI: 10.1177/1078155219901305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
123 Ademiluyi AO, Oboh G, Agbebi OJ, Oyeleye SI. Dietary inclusion of sorghum (Sorghum bicolour) straw dye protects against cisplatin-induced nephrotoxicity and oxidative stress in rats. Pharm Biol 2014;52:829-34. [PMID: 24428129 DOI: 10.3109/13880209.2013.870585] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
124 Moon HH, Seo KW, Yoon KY, Shin YM, Choi KH, Lee SH. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol 2011; 17(30): 3510-3517 [PMID: 21941418 DOI: 10.3748/wjg.v17.i30.3510] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
125 Tian Y, Zhang J, Yan S, Qiu L, Li Z. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer. Lung Cancer 2012;76:416-22. [DOI: 10.1016/j.lungcan.2011.11.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
126 Komaki K, Kusaba T, Tanaka M, Kado H, Shiotsu Y, Matsui M, Shiozaki A, Nakano H, Ishikawa T, Fujiwara H, Konishi H, Itoh Y, Matoba S, Tamagaki K. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study. BMC Cancer 2017;17:144. [PMID: 28219368 DOI: 10.1186/s12885-017-3135-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
127 Sogawa N, Hirai K, Sogawa C, Ohyama K, Miyazaki I, Tsukamoto G, Asanuma M, Sasaki A, Kitayama S. Protective effect of cepharanthin on cisplatin-induced renal toxicity through metallothionein expression. Life Sciences 2013;92:727-32. [DOI: 10.1016/j.lfs.2013.01.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
128 Puvvada SD, Guillén-Rodríguez JM, Yan J, Inclán L, Heard K, Rivera XI, Anwer F, Mahadevan D, Schatz JH, Persky DO. Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study. Oncology 2018;94:274-80. [PMID: 29471300 DOI: 10.1159/000486788] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
129 Kumar G, Solanki MH, Xue X, Mintz R, Madankumar S, Chatterjee PK, Metz CN. Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 2017;313:F339-50. [PMID: 28424213 DOI: 10.1152/ajprenal.00688.2016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
130 Shahbazi F, Sadighi S, Dashti-Khavidaki S, Shahi F, Mirzania M, Abdollahi A, Ghahremani MH. Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Phytother Res 2015;29:1046-53. [PMID: 25857366 DOI: 10.1002/ptr.5345] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
131 Hao J, Lou Q, Wei Q, Mei S, Li L, Wu G, Mi QS, Mei C, Dong Z. MicroRNA-375 Is Induced in Cisplatin Nephrotoxicity to Repress Hepatocyte Nuclear Factor 1-β. J Biol Chem 2017;292:4571-82. [PMID: 28119452 DOI: 10.1074/jbc.M116.754929] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
132 Maimaitiyiming H, Li Y, Cui W, Tong X, Norman H, Qi X, Wang S. Increasing cGMP-dependent protein kinase I activity attenuates cisplatin-induced kidney injury through protection of mitochondria function. Am J Physiol Renal Physiol 2013;305:F881-90. [PMID: 23825069 DOI: 10.1152/ajprenal.00192.2013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
133 Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. The Lancet Oncology 2010;11:670-8. [DOI: 10.1016/s1470-2045(10)70062-0] [Cited by in Crossref: 132] [Cited by in F6Publishing: 66] [Article Influence: 12.0] [Reference Citation Analysis]
134 Magali L, Pascal F, Serge A, Mathieu B, Ayoube Z, Claire T, Christiane M. Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed. Eur J Clin Pharmacol 2020;76:1573-80. [PMID: 32564117 DOI: 10.1007/s00228-020-02935-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Mukhopadhyay S, Sinha N, Das DN, Panda PK, Naik PP, Bhutia SK. Clinical relevance of autophagic therapy in cancer: Investigating the current trends, challenges, and future prospects. Crit Rev Clin Lab Sci 2016;53:228-52. [PMID: 26743568 DOI: 10.3109/10408363.2015.1135103] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
136 Galfetti E, Cerutti A, Ghielmini M, Zucca E, Wannesson L. Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacol Toxicol 2020;21:19. [PMID: 32122396 DOI: 10.1186/s40360-020-0398-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Yamada K, Yoshida T, Zaizen Y, Okayama Y, Naito Y, Yamashita F, Takeoka H, Mizoguchi Y, Yamada K, Azuma K. Clinical Practice in Management of Hydration for Lung Cancer Patients Receiving Cisplatin-based Chemotherapy in Japan: A Questionnaire Survey. Japanese Journal of Clinical Oncology 2011;41:1308-11. [DOI: 10.1093/jjco/hyr145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
138 Fan X, Zhao X, Qu X, Fang J. pH sensitive polymeric complex of cisplatin with hyaluronic acid exhibits tumor-targeted delivery and improved in vivo antitumor effect. Int J Pharm 2015;496:644-53. [PMID: 26529576 DOI: 10.1016/j.ijpharm.2015.10.066] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
139 Leu L, Baribeault D. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract 2010;16:167-71. [PMID: 19759050 DOI: 10.1177/1078155209346071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
140 Karademir LD, Dogruel F, Kocyigit I, Yazici C, Unal A, Sipahioglu MH, Oymak O, Tokgoz B. The efficacy of theophylline in preventing cisplatin-related nephrotoxicity in patients with cancer. Ren Fail 2016;38:806-14. [PMID: 27049176 DOI: 10.3109/0886022X.2016.1163154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
141 Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, Yip P, Chen E, Lee R, Ng P. A case–control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity. J Oncol Pharm Pract 2019;25:875-83. [DOI: 10.1177/1078155218771461] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
142 McKibbin T, Cheng LL, Kim S, Steuer CE, Owonikoko TK, Khuri FR, Shin DM, Saba NF. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support Care Cancer 2016;24:1789-93. [PMID: 26446698 DOI: 10.1007/s00520-015-2978-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
143 Cata JP, Zavala AM, Van Meter A, Williams UU, Soliz J, Hernandez M, Owusu-Agyemang P. Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study. Int J Hyperthermia 2018;34:538-44. [PMID: 28812384 DOI: 10.1080/02656736.2017.1368096] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
144 Li CZ, Jin HH, Sun HX, Zhang ZZ, Zheng JX, Li SH, Han SH. Eriodictyol attenuates cisplatin-induced kidney injury by inhibiting oxidative stress and inflammation. Eur J Pharmacol 2016;772:124-30. [PMID: 26723515 DOI: 10.1016/j.ejphar.2015.12.042] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 9.2] [Reference Citation Analysis]
145 Oh E, Chim H, Soltanian HT. The effects of neoadjuvant and adjuvant chemotherapy on the surgical outcomes of breast reconstruction. J Plast Reconstr Aesthet Surg. 2012;65:e267-e280. [PMID: 22633392 DOI: 10.1016/j.bjps.2012.04.053] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
146 Kanehira Y, Togami K, Tada H, Chono S. Tumor distribution and anti-tumor effect of doxorubicin following intrapulmonary administration to mice with metastatic lung tumor. Journal of Drug Delivery Science and Technology 2016;33:143-8. [DOI: 10.1016/j.jddst.2016.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
147 Chan CY, Li H, Wu MF, Liu CH, Lu HW, Lin ZQ, Li J. A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy. Front Oncol 2021;11:616264. [PMID: 33777754 DOI: 10.3389/fonc.2021.616264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
148 Mizuno T, Sato W, Ishikawa K, Shinjo H, Miyagawa Y, Noda Y, Imai E, Yamada K. KDIGO (Kidney Disease: Improving Global Outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injury. Oncology 2012;82:354-9. [PMID: 22722365 DOI: 10.1159/000338664] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
149 Carvalho Rodrigues MA, dos Santos NA, da Silva Faria MC, Rodrigues JL, Kinoshita A, Baffa O, Antunes LM, Barbosa F Jr, Gobe GC, dos Santos AC. Carvedilol protects the kidneys of tumor-bearing mice without impairing the biodistribution or the genotoxicity of cisplatin. Chem Biol Interact 2016;245:59-65. [PMID: 26751708 DOI: 10.1016/j.cbi.2015.12.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
150 Pabla N, Dong G, Jiang M, Huang S, Kumar MV, Messing RO, Dong Z. Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 2011;121:2709-22. [PMID: 21633170 DOI: 10.1172/JCI45586] [Cited by in Crossref: 106] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
151 Nojiri T, Hosoda H, Kimura T, Miura K, Ishikane S, Tokudome T, Shintani Y, Inoue M, Miyazato M, Okumura M, Kangawa K. Atrial natriuretic peptide protects against cisplatin-induced acute kidney injury. Cancer Chemother Pharmacol 2015;75:123-9. [DOI: 10.1007/s00280-014-2624-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]